Method for predicting therapeutic efficacy of PI3k/AKT/mTOR inhibitor on basis of phlda1 or PIK3C2B expression

• 收藏
• 分享

专利权人:

TAIHO PHARMACEUTICAL CO.; LTD.

发明人:

ABE, TETSUYA,ITADANI, HIRAKU

申请号：

TW103121201

公开号：

TW201537174A

申请日:

2014.06.19

申请国别(地区):

TW

年份:

2015

代理人:

摘要：

The purpose of the present invention is to provide cancer patients with chemotherapy using a PI3K/AKT/mTOR inhibitor that exhibits excellent anti-tumor effects. A method for predicting the therapeutic efficacy of chemotherapy, which uses an anti-tumor agent comprising a PI3K/AKT/mTOR inhibitor, in a cancer patient on the basis of the amount of expression of PHLDA1 and/or PIK3C2B in a biological sample comprising tumor cells collected from the cancer patient.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/